INTRODUCTION {#sec1}
============

Eppstein-Barr Virus--post-transplant-associated lymphoproliferative disease (EBV-PTLD) is well known after kidney transplantation. The incidence varies between 1 and 5% \[[@ref1], [@ref2]\] polymorphic-post-transplant-associated lymphoproliferative disease (P-PTLD) regarding to EBV usually develops in the first year after transplantation \[[@ref1]\]. Recently, EBV-associated mucocutaneous ulcer (EBVMCU) was reported the first time by Dojcinov *et al*. \[[@ref3]\].

CASE REPORT {#sec2}
===========

A 75-year-old male was referred to a proctologist with a symptomatic grade III hemorrhoidal prolapse refractory to conservative treatment and rubber band ligations, a stapled hemorrhoidopexy was performed, without specimen analysis \[[@ref4]\]. Two weeks later, the patient presented with severe urge, frequency and stool fragmentation.

The personal history revealed a living donor human leucocyte antigens (HLA) identical renal transplant in 2003, status after coronary artery bypass and a curatively treated basal cell carcinoma on his back before transplantation. Immunosuppression after transplantation was established with a triple therapy of tacrolimus, mycophenolate-mofetil and prednisone, which was tapered within 3 months to zero. Due to HLA identical transplantation immunosuppression was reduce to mycophenolate mofetil in January 2006.

After the hemorrhoidopexy, he reported of up to 10 bowel movements per day. The symptoms were interpreted as dyssynergy of the pelvic floor and biofeedback therapy involving an anorectal electrostimulator was started. Following this, the patient developed severe anal pain with and after defecation. The complaints were interpreted as an acute anal fissure and again, conservative management involving local nifedipine application and stool regulation were started. However, these measures failed to improve symptoms.

Five months after the initial operation a flexible sigmoidoscopy revealed a large ulceration 3.5 cm from the anal verge ([Fig. 1](#f1){ref-type="fig"}). The consecutively performed magnetic resonance imaging (MRI) suggested a subcutaneous fistula at 6 o'clock.
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In the subsequent examination under anesthesia several ulcerations at 4--5, 6--7 and 10 o'clock were debrided and biopsies were taken and the remaining staples were removed ([Fig. 2](#f2){ref-type="fig"}). The fistula was not detected, probably a localized mucosal intussuseption had mimicked this finding on MRI.

![Examination under anaesthetic.](rjaa057f2){#f2}

The biopsies showed an ulceration of the mucosa with an underlying polymorphic inflammatory infiltrate including several large atypical immunoblastic cells. The latter were positive for CD20, CD30 and EBV (shown by an EBV encode RNA (EBER), in situ hybridization). Stains for human papilloma virus, cytomegalovirus and fungi (PAS-staining) were negative.

In conclusion, the diagnosis of an EBV-associated, P-PTLD with the phenotype of a mucocutaneous ulcer (MCU) was established. A positron emission tomography-computed tomography for the staging of this lymphoproliferative disorder showed an uptake in the transverse colon. The following colonoscopy was inconspicuous. The patient was referred to the oncologist and treating transplant physician, which initiated a therapy with rituximab.

With this therapy, the MCU healed within the following 8 weeks while urge and high frequency only improved slowly. The hemorrhoidal prolapse did not recur and the anal sphincter function was good with no further episodes of incontinence or staining.

DISCUSSION {#sec3}
==========

This is to our knowledge the first report of a MCU diagnosed following a stapled hemorrhoidopexy in an immunosuppressed patient. It remains unclear though whether the MCU was present at the time of the hemorrhoidopexy or if the intervention triggered the development of the condition as no histopathological examination of the resected mucosa at the time of the first operation was performed. Nevertheless, the treating proctologist reported no abnormal ulcerative lesions at the time of the first consultation.

Prieto-Torres *et al*. \[[@ref5]\] described in a study of nine cases the spectrum of the EBVMCU. Every patient had either an immunosuppressive medication or immunosenescence, a rectal involvement was described in two cases, one related to an HIV infection and the other with immunosuppression due to inflammatory bowel disease, unfortunately, no further information was given about the underlying disease and the type of immunosuppressive therapy \[[@ref5]\]. EBVMCU can be split up in two histopathological subtypes with skin and oral tumors or oropharyngeal, rectal and genital ulcers. The latter showed a polymorphic pattern with a Reed-Sternberg or Hodgkin-like appearance. In our case, CD20, CD30 and the EBER were positive ([Fig. 3](#f3){ref-type="fig"}). A polymorphic presentation is typical for the EBVMCU \[[@ref6]\].
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Treatment options in patients with P-PTLD vary widely, depending on patients condition and extent of the disease and the affected organ site. Expectant management with symptomatic treatment as described by Prieto-Torres *et al*. was successful in two patients with rectal lesions. In one of them, the lesions disappeared after several continuous biopsies and the other patient was asymptomatic and had no further diagnostic or treatment \[[@ref5]\]. TK Roberts *et al*. described the therapy options in patients with EBVMCU of two major groups, the iatrogenic immunosuppressed (31 patients) and the age-associated immunosenescence (20 patients). Seventeen patients (68%) of the first group showed a complete remission with reduction of the immunosuppressive therapy. Three patients (12%) received additional rituximab, one patient each (4%) was surgically resected, received R-CHOP chemotherapy (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) and dual antimetabolite and anti-TNFα therapy. All showed a complete clinical response. Nevertheless two patients (8%) died shortly after diagnosis \[[@ref7]\]. This large variety of treatment options has mainly been adopted from the established approach to PTLD at other locations like small bowel. Primarily the reduction of immunosuppressive therapy in addition to rituximab show good results and can be escalated to more aggressive treatment involving R-CHOP or the surgical resection in localized lesions \[[@ref8]\]. In the immunosenescence group radiation was also described, sometimes in combination with chemotherapy \[[@ref7]\].

The most likely etiology of the EBVMCU in our patient was the low-dose immunosuppressive therapy after transplantation, already described by Hart *et al*. \[[@ref9]\]. However, it is remarkable, a rejection reaction under a mycophenolate-mofetil monotherapy is not described in the literature so far. Furthermore, the EBV-associated PTLD arises mostly in the first year after transplantation and correlates with enhanced immunosuppression and rejection treatment, and again this has not been demonstrated in our patient \[[@ref1], [@ref10]\]. Our case report underlines the importance of active surveillance of immunocompromised patients with trivial mucocutaneous findings and their frequent clinical and histopathological follow-up. The treatment with rituximab was safe and well tolerated by the patient and lead to a quick recovery with no signs of recurrence after 6 months.
